The overall objective of Stance4Health is to develop a complete Smart Personalised Nutrition (SPN) service based on the use of mobile technologies as well as tailored food production that will optimize the gut microbiota activity and long-term consumer engagement. The Stance4Health consortium consists of 19 partners from 8 European countries (Spain, Germany, Denmark, Romania, Italy, Greece, Belgium, UK). Six SMEs will be in charge of the development and future commercialisation of the novel SPN service, including 2 new apps for personalised nutrition, integration of a wearable device for daily analysis of one’s body composition, 9 tailored cereal-derived foods for specific (vulnerable) consumer groups (overweight, coeliac disease or food allergy, adults, children), 6 individualised dietary supplements for adults, and 1 nutraceutical and 1 in vitro diagnostic test to control the gut microbiota activity. These novel tools and services have the potential to directly impact more than 67 million European adults and 8 million children by 2022, at a monthly cost of only 0.99€ (for the app).

It is a fact that the European population growth is slowing down, while the population ageing accelerates. Rapid increases in the elderly population are predicted for the coming decades due to the ageing of post-war baby births. Within Europe’s ageing population, Hearing Loss, Cardio Vascular Diseases, Cognitive Impairments, Mental Health Issues and Balance Disorders, as well as Frailty, are prevalent conditions, with tremendous social and financial impact. Preventing, slowing the development of or dealing effectively with the effects of the above impairments can have a significant impact on the quality of life and lead to significant savings in the cost of healthcare services. Digital tools hold the promise for many health benefits that can enhance the independent living and well-being of the elderly. Motivated by the above, the aim of the SMART BEAR platform is to integrate heterogeneous sensors, assistive medical and mobile devices to enable the continuous data collection from the everyday life of the elderly, which will be analysed to obtain the evidence needed in order to offer personalised interventions promoting their healthy and independent living. The platform can also be connected to hospitals and other health care service systems to obtain data of the end-users (e.g., medical history) to be considered in making decisions for interventions. SMART BEAR will leverage big data analytics and learning capabilities, allowing for large scale analysis of the above mentioned collected data, to generate the evidence required for making decisions about personalised interventions. Privacy-preserving and secure by design data handling capabilities, covering data at rest, in processing, and in transit, will cover comprehensively all the components and connections utilized by the SMART BEAR platform. The SMART BEAR solution will be validated through five large-scale pilots involving up to 4.100 elderly living at home in Greece, Italy, France, Portugal and Romania.

The aim of InSilc is to develop an in-silico clinical trial (ISCT) platform for designing, developing and assessing drug-eluting bioresorbable vascular scaffolds (BVS), by building on the comprehensive biological and biomedical knowledge and advanced modelling approaches to simulate their implantation performance in the individual cardiovascular physiology. The InSilc platform is based on the extension of existing multidisciplinary and multiscale models for simulating the drug-eluting BVS mechanical behaviour, the deployment and degradation, the fluid dynamics in the micro- and macroscale, and the myocardial perfusion, for predicting its interaction with the vascular wall in the short- and medium/long term. InSilc goes beyond the design and development of ISCT and lays on the generation of in-silico models for obtaining quick and informed answers to several “What if” scenarios. “Virtual” patients would be given a “virtual” drug-eluting BVS, for observing the performance of the scaffold, assess and quantify the intended effect, with a deeper understanding than normal trials can provide. By integrating the information obtained from different in-silico predictive models, InSilc will: (i) assist in the development, assessment and optimization of the drug-eluting BVS and deliver accurate and reliable information to the Stent Biomedical Industry, (ii) assist the interventional Cardiologists in improving the surgical process of drug-eluting BVS implantation, support them in the clinical assessment and reduce the complications of suboptimal scaffold performance. By introducing computer simulations for establishing the safety and efficacy of drug-eluting BVS, InSilc aims to lower development costs and shorten time-to-market, reduce, refine, and partially replace human clinical trials through a more effective human clinical trials design, reduce the need for animal testing and result in a significant reduction of the associated direct and indirect costs.

With strong growly rates of 13% in the aero sector, and demands predicted to be doubled by 2032, carbon composites (CC) are under the spotlight. CC production requires a quick ramp-up that needs to be based on robust materials & processes and a solid manufacturing supply chain, where higher production rates and cost reduction are essential. The aim of AIRPOXY is to reduce production & MRO costs of CC parts in aeronautics by introducing a new family of enhanced composites that preserve all the advantages of conventional thermosets, while showing new unprecedented features such as Re-processability, Reparability and Recyclability. This will be possible through further development & validation of a family of ground-breaking thermoset resins (recently invented/patented by CID) including dynamic bonds which enable such smart behaviour. Conversion of the technology from TRL3 to 5 will be achieved in AIRPOXY, through 2 representative demonstrators of aircraft panels. Thermoforming processes previously unthinkable for thermosets will reduce manufacturing cost of CC parts by35% vs autoclave, reducing processing times from hours to minutes. Faster/cheaper repair technologies, in combination with SHM, will reduce significantly MRO costs. Additionally, a novel welding process will reduce CC bonding costs by up to 50%. Such new features will foster competitiveness & sustainability in the European aeronautics sector. AIRPOXY relies on a multidisciplinary consortium of 11 partners from 6 countries; CID as resin inventor, key technology providers IVW (thermoforming & welding), EUT(RTM), COEX(SQRTM), UOI(SHM); AEF (process simulation software), aircraft components manufacturers (EIRE, IDEC, SON), standardization experts (UNE) & an aeroconsultancy (ART). They will be supported by a strong advisory board (AIRBUS, Leonardo, Huntsman, SGL and EREA). Maximum impact of AIRPOXY will be ensured through well-balanced dissemination, communication and exploitation activities.